A Study Comparing Daratumumab and Lenalidomide as Maintenance Therapy for Multiple Myeloma

Share
Print

Full Title

Daratumumab Versus Lenalidomide Maintenance Therapy for Multiple Myeloma: A Randomized Pilot Study Comparing Patient-Reported Health Related Quality of Life Measures

Purpose

Lenalidomide is a drug typically used as maintenance therapy in people with multiple myeloma who have responded well to their first round of treatment. Daratumumab is used to treat multiple myeloma when give in combination with other drugs; its use alone is considered investigational.

In this study, researchers are comparing lenalidomide and daratumumab for maintenance therapy in people with multiple myeloma to see if one is better than the other, how they affect patients’ quality of life, and to see if one is easier to take than the other. Patients will be randomly assigned to receive one drug or the other after initial therapy is complete. Lenalidomide is taken orally (by mouth) and daratumumab is given as a subcutaneous (under the skin) injection.

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have completed and responded well to their initial treatment for multiple myeloma.
  • Patients should recover from the serious side effects of previous treatments.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Ola Landgren at 212-639-5126.

Protocol

20-198

Phase

II

Investigator

Co-Investigators